Relmada Therapeutics, Inc (RLMD)

Etorro trading 970x250
Relmada Therapeutics, Inc (RLMD) Logo

About Relmada Therapeutics, Inc

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York. Address: 880 Third Avenue, New York, NY, United States, 10022

Relmada Therapeutics, Inc News and around…

Latest news about Relmada Therapeutics, Inc (RLMD) common stock and company :

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
29 Nov, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
23 Nov, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2021
18 Nov, 2021 FinancialContent

Upgrades Macquarie upgraded the previous rating for ZTO Express (Cayman) Inc (NYSE:ZTO) from Neutral to Outperform. ZTO Express ...

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
11 Nov, 2021 Yahoo! Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced financial results for the three and nine months ended September 30, 2021.

Earnings Scheduled For November 11, 2021
11 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on ...

Relmada Therapeutics to Present at the Jefferies London Healthcare Conference
09 Nov, 2021 Yahoo! Finance

Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will present at the Jefferies London Healthcare Conference on November 17th, 2021 at 8:00am Eastern Time.

Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021
04 Nov, 2021 Yahoo! Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter and nine months ended September 30, 2021 after the market close on Thursday, November 11, 2021. The company will host a conference call and live audio webcast at 4:30 PM Eastern Time on Thursday, November 11, 2021.

Relmada Therapeutics to Present Data at the Neuroscience Education Institute Congress
29 Oct, 2021 Yahoo! Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company's lead product candidate, will be presented in eight poster presentations at the Neuroscience Education Institute (NEI) Congress. The poster session will be held in-person and virtually on Friday, November 5, 2021, from 4:00 to 5:30 PM MST in Colorado Springs, CO. In addition, Relmada is hosting an intera

Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder
04 Oct, 2021 Yahoo! Finance

Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided regulatory and development updates regarding its ongoing late-stage clinical program for REL-1017 in major depressive disorder (MDD).

How The Parts Add Up: VTHR Targets $229
30 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 3000 ETF (VTHR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $228.75 per unit.

Relmada Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
17 Sep, 2021 Yahoo! Finance

Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present at the annual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, on September 21, 2021, at 12:25 pm ET.

Relmada Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
03 Sep, 2021 Yahoo! Finance

Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present at the 19th Annual Morgan Stanley Global Healthcare Conference, on September 10, 2021, at 12:30 pm Eastern Time.

Surprising Analyst 12-Month Target For IBBQ
30 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $32.31 per unit.

Oversold Conditions For Relmada Therapeutics (RLMD)
13 Aug, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Wednesday
11 Aug, 2021 FinancialContent

On Wednesday morning, 67 companies achieved new lows for the year. Areas of Significance: Grifols ...

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
10 Aug, 2021 Yahoo! Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced financial results for the three and six months ended June 30, 2021.

Stocks That Hit 52-Week Lows On Tuesday
10 Aug, 2021 FinancialContent

Before 10 a.m. ET on Tuesday, 60 companies set new 52-week lows. Key Facts: PACCAR (NASDAQ:PCAR) was the ...

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
10 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Earnings Scheduled For August 10, 2021
10 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its ...

Stocks That Hit 52-Week Lows On Monday
09 Aug, 2021 FinancialContent

Before 10 a.m. ET Monday, 63 stocks made new 52-week lows. Intriguing Points: The largest company by market ...

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Relmada Therapeutics to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 10, 2021
05 Aug, 2021 Yahoo! Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter and six-months ended June 30, 2021 after the market close on Tuesday, August 10, 2021. The company will host a conference call and live audio webcast at 4:30 PM Eastern Time on Tuesday, August 10, 2021.

10 Stocks to Buy According to Neil Shahrestani’s Ikarian Capital
03 Aug, 2021 Yahoo! Finance

In this article, we will take a look at the 10 stocks to buy according to Neil Shahrestani’s Ikarian Capital. To skip our detailed analysis of Shahrestani’s history, hedge fund performance, and investment philosophy, go directly to the 5 Stocks to Buy According to Neil Shahrestani’s Ikarian Capital. Neil Shahrestani, MD, is the Chief Investment Officer, managing […]

Down 22.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Relmada Therapeutics, Inc. (RLMD)
30 Jul, 2021 Yahoo! Finance

Relmada Therapeutics, Inc. (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

RLMD June 2022 Options Begin Trading
28 Jul, 2021 FinancialContent

Investors in Relmada Therapeutics Inc (RLMD) saw new options become available today, for the June 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 324 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Relmada Sees Price Target Bump From Leerink, Truist After Positive Data From MDD Candidate
27 Jul, 2021 FinancialContent

SVB Leerinkmaintains an Outperform rating onRelmada Therapeutics Inc(NASDAQ: RLMD) shares as theHuman ...

Here's Why Relmada Therapeutics Stock Popped Today
27 Jul, 2021 FinancialContent

Results from a human abuse potential study with REL-1017 exceeded expectations.

Relmada Therapeutics, Inc (RLMD) is a NASDAQ Common Stock listed in , ,

970x250